JPMorgan Chase & Co.’s efforts to hide trading losses, outlined in a Senate report yesterday, may ignite debate over whether the largest U.S. bank is too big to manage and ratchet up pressure on CEO Jamie Dimon to surrender his role as chairman. Click here to continue reading.
Take a look at our page 1 this week: U.S. notes that allow investors to profit from a steepening of the yield curve surged in January and February. Also inside this issue: Our exclusive, don’t-miss-it table on electronic platforms — who’s doing what, with lots of details. Plus, a look at the Japanese structured notes [...]
CLO s paying the lowest rates in five years are being snapped up by investors, providing the fuel that’s contributing to the biggest surge in corporate buyouts since before the financial crisis. CLICK HERE FOR MORE
by Elizabeth Krutoholow Biogen’s hemophilia drugs may provide a breakthrough for patients by offering protection against bleeding with fewer infusions than standard agents, Dr. Jerry Powell, a hematologist with the UC Davis Comprehensive Cancer Center said in an interview. These drugs will compete against currently marketed recombinant factors like Baxter’s Advate and Pfizer’s [...]
The U.S. Securities and Exchange Commission’s Office of Compliance Inspections and Examinations has completed more than roughly 40 examinations of new investment adviser registrants with more than 80 underway since the end of last year, according to Andrew Bowden, deputy director of OCIE. Click here to continue reading.
Check out the first two pages of the newsletter this week: Euro Stoxx 50 notes were snapped up last month by U.S. investors. Inside the full version: BX Berne scraps a plan to go head to head with Scoach in trading of structured products and Edward Rogers talks about demand for notes in Japan.
Bloomberg Brief will soon be launching a new title: Oil Buyer’s Guide. You can download an exclusive sample here. To take a trial or for subscription information please contact: Annie Gustavson Bloomberg Briefs email@example.com 212-617-0544
Compiled by Andrew Berens, MD, Senior Healthcare Analyst, Bloomberg Industries and Elizabeth Krutoholow Arena and Eisai’s decision to price obesity drug Belviq at a premium to competitor Vivus may create a hurdle for the companies without broad coverage from insurers. Eisai disclosed that the wholesale acquisition cost of Belviq has been set at $199.50 for [...]
Take a free trial to Bloomberg Economic Brief newsletter